<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903899</url>
  </required_header>
  <id_info>
    <org_study_id>LuDO-N</org_study_id>
    <nct_id>NCT04903899</nct_id>
  </id_info>
  <brief_title>177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma</brief_title>
  <acronym>LuDO-N</acronym>
  <official_title>A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jakob Stenman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LuDO-N Trial is a multi-centre phase II clinical trial on 177Lu-DOTATATE treatment of&#xD;
      recurrent or relapsed high-risk neuroblastoma in children. The LuDO-N Trial builds on the&#xD;
      experience from the previous LuDO Trial and utilises an intensified dosing schedule to&#xD;
      deliver 2 doses over a 2-week period, in order to achieve a maximal effect on the often&#xD;
      rapidly progressing disease. This strategy requires a readiness for autologous stem cell&#xD;
      transplantation in all patients, but is not anticipated to increase the risk of long-term&#xD;
      sequelae, since the cumulative radiation dose remains unchanged. The primary aim of the study&#xD;
      is to assess the response to 177Lu-DOTATATE treatment at 1 and 4 months after ende of&#xD;
      treatment. Secondary aims are to assess survival and treatment-related toxicity. Additional&#xD;
      aim are to correlate tumour dosimetry with response, correlate SSTR-2 expression with&#xD;
      68Ga-DOTATATE uptake and to correlate the uptake with the treatment response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">May 20, 2031</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)</measure>
    <time_frame>1 months following end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of treatment-related adverse events</measure>
    <time_frame>Up to 5 years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)</measure>
    <time_frame>4 months following end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from registration to progression or death, up to 5 years following end of treatment</time_frame>
    <description>Time to progress or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from registration to the the date of death, up to 5 years following end of treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumour dosimetry: absorbed dose per administration of 177Lu-DOTATATE</measure>
    <time_frame>At every administered dose of 177Lu-DOTATATE throughout the trial treatment phase (5 years)</time_frame>
    <description>Measured by SPECT/CT</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of expression of Somatostatin Receptor-2 (SSTR-2) to uptake on 68Ga-DOTATOC PET/CT</measure>
    <time_frame>Throughout the trial treatment phase (5 years)</time_frame>
    <description>SSTR-2 expression in the histology samples from primary surgery measured by immunohistochemistry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Uptake on 68Ga-DOTATOC PET/CT</measure>
    <time_frame>At end of treatment, and 1 and 4 months after end of treatment.</time_frame>
    <description>Measured by SUVmax (maximum standardized uptake value)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neuroblastoma Recurrent</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>177Lu-DOTATATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of two doses of 177Lu-DOTATATE will be administered intravenously. The minimum time between treatments is 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>177Lu-DOTATATE</intervention_name>
    <description>A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.</description>
    <arm_group_label>177Lu-DOTATATE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathology 1.1. Histologically confirmed diagnosis of neuroblastoma 1.2.&#xD;
             Immunohistochemical staining for somatostatin receptors (SSTR) performed from primary&#xD;
             tumor tissue when available&#xD;
&#xD;
          2. Relapsed or primary refractory high-risk neuroblastoma: International Neuroblastoma&#xD;
             Staging System (INSS) stage 4 disease or International Neuroblastoma Risk Group&#xD;
             Staging System (INRGSS) stage M disease&#xD;
&#xD;
          3. Age &gt;18 months and &lt; 18 years of age at the time of enrolment into this study&#xD;
&#xD;
          4. Life expectancy of greater than 3 months&#xD;
&#xD;
          5. Performance Status 5.1. Karnofsky &gt; 50% (for patients &gt; 12 years of age) 5.2. Lansky &gt;&#xD;
             50% (for patients ≤ 12 years of age)&#xD;
&#xD;
          6. Prior treatment 6.1. Two-week washout from any prior treatment 6.2. Patients must have&#xD;
             recovery of hematological toxicity following previous therapy 6.3. Adequate recovery&#xD;
             from major surgery prior to receiving study treatment&#xD;
&#xD;
          7. Diagnostic imaging 7.1. Uptake in the primary tumor or metastatic tumour deposits on&#xD;
             68Ga-DOTATATE PET/CT at least higher than the liver uptake and performed within two&#xD;
             months prior to registration 7.2. 123I-mIBG scintigraphy to be performed within two&#xD;
             months prior to registration 7.3. CT or MRI of the primary tumor and bulky metastatic&#xD;
             sites within two months prior to registration&#xD;
&#xD;
          8. Laboratory requirements to be performed within 7 days prior to commencing trial&#xD;
             treatment 8.1. Hematology: 8.1.1. Hemoglobin, If Hb is &lt;120 g/L then patient will&#xD;
             receive a blood transfusion prior to commencing trial treatment 8.1.2. Absolute&#xD;
             neutrophil count &gt; 1.0 x 109/L 8.1.3. Absolute Platelets &gt; 100 x 109/L 8.2.&#xD;
             Biochemistry: 8.2.1. Bilirubin within 1.5 x ULN 8.2.2. ALT within 2.5 x ULN 8.2.3. AST&#xD;
             within 2.5 x ULN 8.2.4. GGT within 5 x ULN 8.2.5. ALP within 5 x ULN 8.2.6. Glomerular&#xD;
             filtration rate &gt;50mL/min/1.73m2 assessed by a recognised method, such as inulin,&#xD;
             51Cr-EDTA, 99mTc-DTPA or iohexol clearance and performed within 2 months prior to&#xD;
             registration 8.2.7. Urinary catecholamine metabolites measured within 2 months prior&#xD;
             to registration&#xD;
&#xD;
          9. Peripheral blood stem cells (PBSC) 9.1. A minimum of 4 x106 CD34+ cells/kg (optimally&#xD;
             6 x106 CD34+ cells/kg) must be available for each study subject prior to registering&#xD;
&#xD;
         10. Written informed consent from patient and/or parent(s) or legal guardian(s) in&#xD;
             accordance with national regulations, prior to registration or any trial-related&#xD;
             screening procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not fit enough to undergo proposed study treatment, as assessed by national PI,&#xD;
             considering precautions defined in the latest version of the Lutathera SmPC&#xD;
&#xD;
          2. Pregnant or lactating patient&#xD;
&#xD;
          3. Concurrent treatment with any anti-tumor agents&#xD;
&#xD;
          4. Prior treatment with other radiolabeled somatostatin analogues&#xD;
&#xD;
          5. Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient or legal guardian before registration in the&#xD;
             trial&#xD;
&#xD;
          6. Hypersensitivity to any component of the investigational drug Lutathera®&#xD;
&#xD;
          7. Treatment with long-acting somatostatin analogues within 30 days prior the&#xD;
             administration of Lutathera®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Stenman, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jakob Stenman, MD PhD</last_name>
    <phone>(0)51770000</phone>
    <phone_ext>46</phone_ext>
    <email>jakob.stenman@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kleopatra Georgantzi, MD</last_name>
    <phone>(0)51770000</phone>
    <phone_ext>46</phone_ext>
    <email>kleopatra.georgantzi@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper S Brok, MD PhD</last_name>
      <email>jesper.sune.brok@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jesper S Brok, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Children's Hospital, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>HUS</state>
        <zip>FI-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minna Koskenvuo, MD PhD</last_name>
      <email>minna.koskenvuo@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Minna Koskenvuo, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jelena Rascon, MD PhD</last_name>
      <email>jelena.rascon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Rascon, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center for Pediatric Oncology</name>
      <address>
        <city>Utrecht</city>
        <zip>NL-3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max M van Noesel, MD PhD</last_name>
      <email>M.M.vanNoesel@prinsesmaximacentrum.nl</email>
    </contact>
    <investigator>
      <last_name>Max M van Noesel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Brunsvig Jarvis, MD</last_name>
      <email>kirjar@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Kirsten Brunsvig Jarvis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kleopatra Georgantzi, MD</last_name>
      <email>kleopatra.georgantzi@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Jakob Stenman, MD PhD</last_name>
      <email>jakob.stenman@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Kleopatra Georgantzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jakob Stenman</investigator_full_name>
    <investigator_title>Consultant Pediatric Surgeon, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

